BMO Capital Markets Reiterates “Buy” Rating for Zoetis Inc. (ZTS), Report finds

BMO Capital Markets Reiterates “Buy” Rating for Zoetis Inc. (ZTS), Report finds

Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating reissued by analysts at BMO Capital Markets in a research note issued on Wednesday. They presently have a $60.00 price objective on the stock. BMO Capital Markets’ price objective suggests a potential upside of 7.22% from the company’s current price.

Several other equities analysts have also commented on ZTS. Stifel Nicolaus reaffirmed a “buy” rating and issued a $58.00 price target on shares of Zoetis in a research note on Wednesday, October 12th. Zacks Investment Research lowered Zoetis from a “hold” rating to a “sell” rating in a research note on Thursday, October 13th. Jefferies Group LLC reissued a “buy” rating and set a $63.00 target price on shares of Zoetis in a research note on Sunday, October 16th. Finally, J P Morgan Chase & Co reissued a “hold” rating and set a $53.00 target price on shares of Zoetis in a research note on Thursday, November 3rd. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $57.73.

Shares of Zoetis (NYSE:ZTS) traded down 0.04% during midday trading on Wednesday, hitting $55.96. The company had a trading volume of 2,888,874 shares. The firm has a market capitalization of $27.63 billion, a PE ratio of 40.35 and a beta of 1.07. Zoetis has a 12 month low of $38.26 and a 12 month high of $56.32. The company has a 50-day moving average of $54.08 and a 200 day moving average of $51.55.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 1st. Stockholders of record on Friday, January 20th will be issued a $0.105 dividend. The ex-dividend date of this dividend is Wednesday, January 18th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.75%. This is an increase from Zoetis’s previous quarterly dividend of $0.10. Zoetis’s dividend payout ratio is presently 30.44%.

In related news, insider Kristin C. Peck sold 10,092 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $49.55, for a total value of $500,058.60. Following the completion of the sale, the insider now directly owns 22,768 shares of the company’s stock, valued at approximately $1,128,154.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.05% of the company’s stock.

Several hedge funds have recently made changes to their positions in ZTS. LS Investment Advisors LLC boosted its stake in shares of Zoetis by 25.2% in the second quarter. LS Investment Advisors LLC now owns 16,614 shares of the company’s stock worth $789,000 after buying an additional 3,349 shares during the period. First Citizens Bank & Trust Co. purchased a new stake in shares of Zoetis during the second quarter worth about $587,000. Henderson Group PLC boosted its stake in shares of Zoetis by 1.7% in the second quarter. Henderson Group PLC now owns 73,089 shares of the company’s stock worth $3,468,000 after buying an additional 1,200 shares during the period. Nordea Investment Management AB boosted its stake in shares of Zoetis by 0.7% in the second quarter. Nordea Investment Management AB now owns 24,432 shares of the company’s stock worth $1,160,000 after buying an additional 163 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Zoetis by 0.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 6,730 shares of the company’s stock worth $319,000 after buying an additional 26 shares during the period. 93.85% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Related posts

Leave a Comment

BMO Capital Markets Reiterates “Buy” Rating for Zoetis Inc. (ZTS)

BMO Capital Markets Reiterates “Buy” Rating for Zoetis Inc. (ZTS)

Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating reissued by analysts at BMO Capital Markets in a research note issued on Wednesday. They presently have a $60.00 price objective on the stock. BMO Capital Markets’ price objective suggests a potential upside of 7.22% from the company’s current price.

Several other equities analysts have also commented on ZTS. Stifel Nicolaus reaffirmed a “buy” rating and issued a $58.00 price target on shares of Zoetis in a research note on Wednesday, October 12th. Zacks Investment Research lowered Zoetis from a “hold” rating to a “sell” rating in a research note on Thursday, October 13th. Jefferies Group LLC reissued a “buy” rating and set a $63.00 target price on shares of Zoetis in a research note on Sunday, October 16th. Finally, J P Morgan Chase & Co reissued a “hold” rating and set a $53.00 target price on shares of Zoetis in a research note on Thursday, November 3rd. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $57.73.

Shares of Zoetis (NYSE:ZTS) traded down 0.04% during midday trading on Wednesday, hitting $55.96. The company had a trading volume of 2,888,874 shares. The firm has a market capitalization of $27.63 billion, a PE ratio of 40.35 and a beta of 1.07. Zoetis has a 12 month low of $38.26 and a 12 month high of $56.32. The company has a 50-day moving average of $54.08 and a 200 day moving average of $51.55.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 1st. Stockholders of record on Friday, January 20th will be issued a $0.105 dividend. The ex-dividend date of this dividend is Wednesday, January 18th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.75%. This is an increase from Zoetis’s previous quarterly dividend of $0.10. Zoetis’s dividend payout ratio is presently 30.44%.

In related news, insider Kristin C. Peck sold 10,092 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $49.55, for a total value of $500,058.60. Following the completion of the sale, the insider now directly owns 22,768 shares of the company’s stock, valued at approximately $1,128,154.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.05% of the company’s stock.

Several hedge funds have recently made changes to their positions in ZTS. LS Investment Advisors LLC boosted its stake in shares of Zoetis by 25.2% in the second quarter. LS Investment Advisors LLC now owns 16,614 shares of the company’s stock worth $789,000 after buying an additional 3,349 shares during the period. First Citizens Bank & Trust Co. purchased a new stake in shares of Zoetis during the second quarter worth about $587,000. Henderson Group PLC boosted its stake in shares of Zoetis by 1.7% in the second quarter. Henderson Group PLC now owns 73,089 shares of the company’s stock worth $3,468,000 after buying an additional 1,200 shares during the period. Nordea Investment Management AB boosted its stake in shares of Zoetis by 0.7% in the second quarter. Nordea Investment Management AB now owns 24,432 shares of the company’s stock worth $1,160,000 after buying an additional 163 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Zoetis by 0.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 6,730 shares of the company’s stock worth $319,000 after buying an additional 26 shares during the period. 93.85% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Related posts

Leave a Comment